Skip to Main Content

Paper Details

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
Cancer
5
2023
ADVL1312, ATRX, AZD1775, Patient, Tumor, WEE1, WEE1 kinase, adavosertib, central nervous system embryonal tumors, irinotecan, medulloblastoma, neuroblastoma, patient, patients, pediatric, pineoblastoma, rhabdomyosarcoma, solid tumor, telomeres, tumor, tumors
Author NameAffiliation
Kristina A ColeChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
Kristina A ColeChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
Heba IjazChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
Lea F SurreyChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
Mariarita SantiChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
Mariarita SantiChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
John M MarisChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
John M MarisChildren's Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania
  • 1 - 8

Datasets

Release 1.2